(Q36022779)

11 August 2017

1 reference

title

Chemotherapy options and new advances in malignant pleural mesothelioma (English)

1 reference

11 August 2017

1 reference

J P C Steele

1

1 reference

11 August 2017

A Klabatsa

series ordinal

2

1 reference

11 August 2017

publication date

27 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

16

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

345-351

1 reference

Analysis of current trends in United States mesothelioma incidence

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

The European mesothelioma epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Diffuse malignant mesothelioma. Prospective evaluation of 69 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Prognostic factors in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Weekly high-dose cisplatin in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

The alpha folate receptor is highly activated in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

The role of gemcitabine in the treatment of malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Chemotherapy for malignant pleural mesothelioma: past results and recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

A Multicenter Phase II Study of Gemcitabine and Oxaliplatin for Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Pemetrexed disodium, a novel antifolate with multiple targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

The new front line treatment for malignant pleural mesothelioma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Prospects for an SV40 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI094

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDI094

1 reference

11 August 2017

1 reference